APA

Carmona Martinez A., Salamanca de la Cueva I., Boutet P., Vanden Abeele C., Smolenov I. & Devaster J. (20160222). A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months. : Human vaccines & immunotherapeutics.

Chicago

Carmona Martinez Alfonso, Salamanca de la Cueva Ignacio, Boutet Philippe, Vanden Abeele Carline, Smolenov Igor and Devaster Jeanne-Marie. 20160222. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months. : Human vaccines & immunotherapeutics.

Harvard

Carmona Martinez A., Salamanca de la Cueva I., Boutet P., Vanden Abeele C., Smolenov I. and Devaster J. (20160222). A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months. : Human vaccines & immunotherapeutics.

MLA

Carmona Martinez Alfonso, Salamanca de la Cueva Ignacio, Boutet Philippe, Vanden Abeele Carline, Smolenov Igor and Devaster Jeanne-Marie. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months. : Human vaccines & immunotherapeutics. 20160222.